CSIMarket
 
Vir Biotechnology Inc   (VIR)
Other Ticker:  
 
 
Price: $10.6800 $-0.08 -0.743%
Day's High: $10.9 Week Perf: -0.47 %
Day's Low: $ 10.59 30 Day Perf: 3.59 %
Volume (M): 1,112 52 Wk High: $ 27.48
Volume (M$): $ 11,871 52 Wk Avg: $15.14
Open: $10.90 52 Wk Low: $7.72



 Market Capitalization (Millions $) 1,431
 Shares Outstanding (Millions) 134
 Employees -
 Revenues (TTM) (Millions $) 86
 Net Income (TTM) (Millions $) -615
 Cash Flow (TTM) (Millions $) -607
 Capital Exp. (TTM) (Millions $) 22

Vir Biotechnology Inc
Vir Biotechnology Inc is a clinical-stage immunology company focused on developing therapies to treat infectious diseases.
The company was founded in 2016 by George Scangos, a former CEO of Biogen.
The company has its headquarters in San Francisco, California and operates in the United States and the United Kingdom.
Vir is focused on developing treatments for viral infections such as hepatitis B virus, respiratory syncytial virus (RSV), influenza, and novel coronaviruses like SARS-CoV-2.
The company is looking to leverage its expertise in immunology and virology to develop novel treatments that can improve patient outcomes and reduce the spread of infectious diseases.
Vir has a diverse pipeline of product candidates, including monoclonal antibodies, antivirals, and vaccines, that are being developed for a range of viral infections.
The company has several partnerships and collaborations with leading pharmaceutical companies, including GlaxoSmithKline, Biogen, and Alnylam.
Vir has a strong management team and scientific advisory board, comprising experts in virology, immunology, and drug development.
The company has raised over $2 billion in funding to support its research and development efforts.
Overall, Vir Biotechnology Inc is a promising biotech company with a focus on developing innovative treatments for infectious diseases.
With a strong pipeline of product candidates and partnerships with established pharmaceutical companies, the company is well-positioned to make a significant impact in the fight against viral infections.


   Company Address: 1800 Owens Street San Francisco 94158 CA
   Company Phone Number: 906-4324   Stock Exchange / Ticker: NASDAQ VIR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Vir Biotechnology Inc

Vir Biotechnology Inc Faces Larger Loss in Latest Fiscal Period, But Shows Signs of Recovery

Despite the recent disappointing fiscal period declared by Vir Biotechnology Inc, there are signs of potential growth and recovery for the company. While revenue saw a significant decline of -66.025%, it is important to note that revenue doubled sequentially from the previous reporting period, showing signs of improvement. Additionally, the company reported a net loss per share that widened from the prior year, but they are taking steps to address this issue.
One positive development for Vir Biotechnology Inc is their participation in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference. This shows that the company is actively engaging with industry experts and working on solutions to tackle challenging issues in the biotechnology and pharmaceuticals sector. This proactive approach is a good sign for investors who are looking for long-term growth potential.

Vir Biotechnology Inc

Vir Biotechnology Inc. Faces Steep Deterioration Amid Disastrous Q3 2023 Financial Report

Breaking News: Vir Biotechnology Inc. to Bounce Back Stronger Than Ever
In a surprising turn of events, Vir Biotechnology Inc. reported a disastrous third quarter of 2023 financial report, sending shockwaves through the stock market. However, astute investors understand that one poor quarter does not define a company's trajectory. Instead of dwelling on the negatives, let's look at the broader picture and explore the exciting prospects that lie ahead for Vir Biotechnology Inc.
To begin with, it's crucial to acknowledge the financial setbacks Vir Biotechnology Inc. experienced during this quarter. Revenue faded by a jaw-dropping -99.295%, plummeting to $2.64 million. Even more concerning, the net deficit per share has swelled to $-1.22, representing a significant increase from the previous year. Revenue tumbled by -30.498% compared to the preceding reporting period, reflecting the challenging circumstances faced by the company.

Vir Biotechnology Inc

Exploring Vir Biotechnology Inc's Challenging Second Quarter Performance in 2023



The stock market provides a platform for investors to gauge the performance of various companies. One such company that has caught the attention of many investors is Vir Biotechnology Inc (VIR). In the financial second quarter of 2023, VIR experienced a significant decline in its performance, with revenue tumbling and a larger net shortfall than the previous year. Let's dive into the interesting facts surrounding VIR's financial performance during this period.
Decreased Earnings Per Share (EPS):
Compared to the financial reporting period a year ago, VIR's EPS saw a substantial decline. In Q2 2023, there was a shortfall per share of $-1.45, compared to $-0.58 per share recorded in the same period last year. This figure indicates a decrease in earnings and may cause concern among investors.

Vir Biotechnology Inc

Vir Biotechnology Inc Faces Devastating Financial Losses in Latest Fiscal Quarter

Vir Biotechnology Inc is a biopharmaceutical company that focuses on developing innovative therapies for a range of serious infectious diseases. The company's pipeline includes treatments for HIV, hepatitis B, influenza, and COVID-19, among others.
However, the company recently disclosed a disastrous financial report for the first quarter ending March 31, 2023. According to the report, the company's revenue plummeted by an alarming 94.892% to $62.96 million, compared to the same period a year ago. The net deficit per share also skyrocketed to $-1.06, up from $-0.73 per share last year.






 

Vir Biotechnology Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Vir Biotechnology Inc does not provide revenue guidance.

Earnings Outlook
Vir Biotechnology Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com